NASDAQ:OKYO

OKYO Pharma Q2 2027 Earnings Date & Estimates

OKYO Pharma logo
$1.09 -0.07 (-6.38%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OKYO Pharma is estimated to report Q2 2027 earnings on Wednesday, December 2, 2026. The conference call is scheduled for November 30, 2026 at 2:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Conference Call Date
Conference Call
2:00 AM ET

What Analysts Expect from OKYO Pharma in Q2 2027

OKYO Pharma is expected to post earnings of -$0.06 per share. OKYO Pharma last reported on January 30, 2026, posting -$2.2750 per share and missing the -$0.07 consensus estimate.

Consensus Estimates

Consensus EPS
-$0.06

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.2750 (Missed by -$2.2050)

OKYO Pharma Q2 2027 Earnings FAQ

OKYO Pharma (NASDAQ:OKYO) is estimated to report Q2 2027 earnings on Wednesday, December 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

OKYO Pharma's Q2 2027 earnings conference call is scheduled for Monday, November 30, 2026 at 2:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect OKYO Pharma to post earnings of -$0.06 per share for Q2 2027.

OKYO Pharma Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More OKYO Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email.

About OKYO Pharma

OKYO Pharma (NASDAQ:OKYO) Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye.

The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.

View OKYO Pharma Profile